Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

136P - Germline testing in a cohort of malignant mesothelioma (G-MESO)


31 Mar 2023


Poster Display session


Ernest Nadal


Journal of Thoracic Oncology (2023) 18 (4S): S116-S118.


E. Nadal1, M. Gausachs2, C. Castillo3, A. Teule3, J. Brenes3, M. Jove3, R. Palmero4, M. Mosteiro3, S. Padrones5, J. Bosch-Barrera6, M. Pineda3, E. Tornero3, A. Alay3, A. Lopez-doriga3, I. Brao3, M. Arellano3, J. Brunet7, C. Lazaro3

Author affiliations

  • 1 ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat/ES
  • 2 Bellvitge Biomedical Research Institute (IDIBELL)., L’Hospitalet de Llobregat (Barcelona)/ES
  • 3 ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L’Hospitalet de Llobregat (Barcelona)/ES
  • 4 Catalan Institute of Oncology, Barcelona/ES
  • 5 Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat (Barcelona)/ES
  • 6 ICO Girona - Institut Català d'Oncologia Girona, 17007 - Girona/ES
  • 7 ICO Girona - Institut Català d'Oncologia Girona, Girona/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 136P


Malignant mesothelioma (MM) is associated with asbestos exposure and about 10–15% of patients are carriers of germline pathogenic or likely pathogenic variants (GPV/GLPV) in genes associated with cancer predisposition. The prevalence of GPV/GLPV in patients diagnosed with MM in our country is unknown.


All patients signed the informed consent and were prospectively tested using a custom NGS panel covering 164 cancer-predisposing genes. We present preliminary results from a cohort of 66 patients diagnosed with pleural and peritoneal malignant mesothelioma (MM) at the Catalan Institute of Oncology.


Median age was 70.5 (46–88) and 70% were males. 60 patients had pleural and 6 peritoneal MM and most patients had epithelioid MM (86%). Most patients had history or probable exposure to asbestos (44% and 23%, respectively). Nine patients had personal history of cancer and 44 (67%) had family history of cancer (first degree relative). Eight patients (12.1%) harbored GPV/GLPV in 6 genes: BAP1 (n = 2), BARD1 (n = 2), FANCA (n = 1), RECQL4 (n = 1), SBDS (n = 1), SDHC (n = 1). Five patients (7.5%) were referred to Genetic Counselling. Patients with GPV/GLPV compared to their counterparts were more likely to have personal and family history of cancer, lack of asbestos exposure, however these differences were not statistically significant probably due to the limited statistical power (table). We will present updated results of this study at the ELCC 2023.

Table: 136P

Clinicopathological and epidemiological features of carriers of GPV/GLPV with their counterparts

GPV/GLPV (n = 8)No GPV/GLPV (n = 58)P-value
Age, median (range)69 (46–86)70.5 (52–88)0.302
Gender, n (%) Male Female7 (87.5%) 1 (12.5%)39 (67%) 19 (33%)0.418
Asbestos exposure, n (%) Yes Probable No1 (12.5%) 2 (25%) 5 (62.5%)28 (48.3%) 13 (22.4%) 17 (29.3%)0.111
Personal history of cancer, n (%) Yes No2 (25%) 6 (75%)7 (12%) 50 (88%)0.305
Family history of cancer, n (%) Yes No7 (87.5%) 1 (12.5%)37 (67%) 18 (33%)0.417
Mesothelioma location, n (%) Pleural Peritoneal6 (75%) 2 (25%)54 (93%) 4 (7%)0.151
Histological subtype, n (%) Epithelioid Non-epithelioid7 (87.5%) 1 (12.5%)50 (86%) 8 (14%)0.702


In this series, 12.1% of patients with malignant mesothelioma harbored GPV/GLPV and 7.5% were candidates to be referred to Genetic Counselling. Germline molecular testing should be considered in patients diagnosed with MM.

Legal entity responsible for the study

Catalan Institute of Oncology.




E. Nadal: Financial Interests, Personal, Advisory Board: Roche, Bristol Myers Squibb, Merck Sharp Dohme, Boehringer Ingelheim, Eli Lilly, Janssen, Pfizer, Merck Serono, Daiichi Sankyo, AstraZeneca, Takeda, Amgen, Sanofi; Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck Sharp Dohme, Boehringer Ingelheim, Eli Lilly, Pfizer, Sanofi, AstraZeneca, Takeda, Amgen; Financial Interests, Personal and Institutional, Funding, Clinical trial funded by Roche: Roche; Financial Interests, Personal and Institutional, Funding, BMS funded a clinical trial: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Funding, Merck Serono funded a clinical trial: Merck Serono. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.